Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00. Following the completion of the sale, the insider owned 10,503 shares of the company’s stock, valued at approximately $266,461.11. This represents a 41.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Up 0.4%

NASDAQ MAZE opened at $27.27 on Monday. The firm has a market cap of $1.36 billion, a PE ratio of -8.44 and a beta of 2.50. The company has a 50 day moving average price of $36.92 and a 200 day moving average price of $38.18. Maze Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08. On average, equities research analysts anticipate that Maze Therapeutics, Inc. will post -2.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Candriam S.C.A. acquired a new position in Maze Therapeutics during the 1st quarter valued at approximately $8,303,000. Y Intercept Hong Kong Ltd acquired a new position in Maze Therapeutics during the 1st quarter valued at approximately $649,000. Ground Swell Capital LLC acquired a new position in Maze Therapeutics during the 1st quarter valued at approximately $406,000. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics during the 4th quarter valued at approximately $145,000. Finally, Invesco Ltd. increased its stake in Maze Therapeutics by 1.5% during the 4th quarter. Invesco Ltd. now owns 134,033 shares of the company’s stock valued at $5,553,000 after purchasing an additional 1,971 shares in the last quarter.

Analyst Ratings Changes

MAZE has been the subject of several recent analyst reports. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Truist Financial reduced their price objective on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, April 14th. Guggenheim boosted their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. HC Wainwright upped their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.